Country Club Trust Company N.a. buys $4,379,716 stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Country Club Trust Company N.a. scooped up 126 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 14, 2016. The investment management firm now holds a total of 28,869 shares of Thermo Fisher Scientific which is valued at $4,379,716.Thermo Fisher Scientific makes up approximately 0.63% of Country Club Trust Company N.a.’s portfolio.

Other Hedge Funds, Including , Forte Capital Adv reduced its stake in TMO by selling 400 shares or 4.07% in the most recent quarter. The Hedge Fund company now holds 9,418 shares of TMO which is valued at $1,431,819. Thermo Fisher Scientific makes up approx 0.55% of Forte Capital Adv’s portfolio.Genesee Valley Trust Co reduced its stake in TMO by selling 5 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 4,451 shares of TMO which is valued at $689,460. Thermo Fisher Scientific makes up approx 0.45% of Genesee Valley Trust Co’s portfolio. Simplex Trading sold out all of its stake in TMO during the most recent quarter. The investment firm sold 381 shares of TMO which is valued $60,278.Telemus Capital boosted its stake in TMO in the latest quarter, The investment management firm added 1,625 additional shares and now holds a total of 26,242 shares of Thermo Fisher Scientific which is valued at $4,153,584. Thermo Fisher Scientific makes up approx 0.46% of Telemus Capital’s portfolio.

Thermo Fisher Scientific closed down -0.32 points or -0.21% at $151.71 with 14,77,936 shares getting traded on Friday. Post opening the session at $152.89, the shares hit an intraday low of $151.5 and an intraday high of $152.93 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.